Dr. Lekakis on Current Research With CAR T-Cell Therapy

Video

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Bispecific CAR T cells are an area of active investigation in B-cell malignancies, explains Lekakis. Currently, tisagenlecleucel (Kymriah) and axicabtagene-ciloleucel (Yescarta) are approved for patients with relapsed or refractory diffuse large B-cell lymphoma, both of which target CD19. Some of the dual targets under investigation include CD19 and CD22. Dual-targeted CAR T cells may be more effective, explains Lekakis as CAR T-cell evasion can occur with CD19 clones, he explains.

In multiple myeloma, several products are under investigation—–all of which target BCMA. Some companies are combining CAR T cells with PD-1/PD-L1 inhibitors to try to evade T-cell exhaustion, explains Lekakis. Combinations of CD19-specific CAR T cells and lenalidomide (Revlimid) and rituximab (Rituxan) are also under exploration, adds Lekakis.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.